Chronic graft-versus-host disease of the liver: Presentation as an acute hepatitis

Authors

  • Simone I. Strasser,

    1. Gastroenterology/Hepatology, Pathology, and Long-Term Follow-Up Programs, Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA
    Current affiliation:
    1. A. W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
    Search for more papers by this author
  • Howard M. Shulman,

    1. Gastroenterology/Hepatology, Pathology, and Long-Term Follow-Up Programs, Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA
    Search for more papers by this author
  • Mary E. Flowers,

    1. Gastroenterology/Hepatology, Pathology, and Long-Term Follow-Up Programs, Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA
    Search for more papers by this author
  • Rajender Reddy,

    1. University of Miami School of Medicine, Miami, FL
    Search for more papers by this author
  • David A. Margolis,

    1. Childrens' Hospital of Wisconsin, Milwaukee, WI
    Search for more papers by this author
  • Manfred Prumbaum,

    1. University of Essen, Essen, Germany
    Search for more papers by this author
  • Stuart E. Seropian,

    1. Yale University School of Medicine, New Haven, CT
    Search for more papers by this author
  • George B. McDonald

    Corresponding author
    1. Gastroenterology/Hepatology, Pathology, and Long-Term Follow-Up Programs, Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA
    • Gastroenterology/Hepatology Section, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N. (D2-190), P.O. Box 19024, Seattle, WA 98109-1024
    Search for more papers by this author

Abstract

Chronic graft-versus-host disease (GVHD) of the liver usually presents as an indolent cholestatic disease in patients with skin, mouth, and eye involvement. We observed 14 patients in whom chronic GVHD of the liver presented with marked elevations of serum aminotransferases, clinically resembling acute viral hepatitis. Onset of liver dysfunction was at 294 days (range, 74-747 days) after allogeneic hematopoietic cell transplantation and coincided with a recent cessation or taper of immunosuppressive drugs. Median peak serum alanine transaminase (ALT) was 1,640 U/L (698-2,565 U/L), and median bilirubin was 12.3 mg/dL (0.9-55.9 mg/dL). All biopsies showed characteristic features of GVHD with damaged and degenerative small bile ducts. Other features included a marked lobular hepatitis, moderate to marked amounts of hepatocyte unrest, sinusoidal inflammation with perivenular necroinflammatory foci, and many acidophilic bodies scattered throughout the lobule. When high-dose immunosuppressive therapy was instituted soon after presentation, progressive improvement and eventual normalization of liver enzymes and bilirubin levels were observed. However, in cases in which the diagnosis was not made and therapy was delayed, a progressive cholestatic picture emerged with histologic evidence of loss of small bile ducts and portal fibrosis. We conclude that a distinct syndrome of chronic liver GVHD presenting as an acute hepatitis can be recognized in a patient at risk who is receiving no, or minimal, immunosuppressive medications. Liver biopsy is necessary to exclude viral causes of liver dysfunction and to confirm characteristic abnormalities of small bile ducts. Institution of high-dose immunosuppression can prevent progressive bile duct destruction and effect resolution of jaundice if given early.

Ancillary